DOUGLAS RICHARD 4
Research Summary
AI-generated summary
MaxCyte Director Douglas Richard Receives RSU Award
What Happened Douglas Richard, a member of MaxCyte, Inc.'s (MXCT) board of directors, was granted a total of 80,000 restricted stock units (RSUs) on June 17, 2026. The grant consists of 30,421 RSUs reported as a direct award and 49,579 RSUs reported as a derivative award. No cash was paid for these awards (acquisition price $0).
Key Details
- Transaction date: June 17, 2026; Filing date (Form 4): June 22, 2026 (filed 5 days after the transaction).
- Price: $0.00 per RSU (awarded, not purchased).
- Shares: 30,421 direct RSUs + 49,579 derivative RSUs = 80,000 RSUs total.
- Vesting: Shares underlying this annual director grant vest on June 17, 2027, subject to the reporting person's continuous service on the vesting date (per footnote).
- Footnotes: F1 clarifies each RSU is a contingent right to one share of common stock; F2 states this is an annual grant under the company’s Equity Grant Policy for non-employee directors.
- Shares owned after transaction: Not specified in the filing.
- Timeliness: Filing appears late relative to the usual Form 4 requirement (filed 5 days after the June 17 transaction).
Context RSUs are awards representing the right to receive shares in the future if vesting conditions are met; they are not open‑market purchases or sales. This grant is a routine, compensation-related award for a non-employee director and does not by itself indicate buying or selling sentiment. The derivative-classed portion simply reflects reporting convention for contingent rights to receive shares.